Correlates of protection for meningococcal surface protein vaccines: current approaches for the determination of breadth of coverage

References

• Parikh SR, Campbell H, Bettinger JA, et al. The everchanging epidemiology of meningococcal disease worldwide and the potential for prevention through vaccination. J Infect. 2020;81(4):483–498.
   PubMed Web of Science ®Google Scholar
• Purmohamad A, Abasi E, Azimi T, et al. Global estimate of Neisseria meningitidis serogroups proportion in invasive meningococcal disease: a systematic review and meta-analysis. Microb Pathog. 2019; 134:103571.
   Google Scholar
• Tan LK, Carlone GM, Borrow R. Advances in the development of vaccines against Neisseria meningitidis. N Engl J Med. 2010;362(16):1511–1520.
   PubMed Web of Science ®Google Scholar
• Rosenstein NE, Perkins BA, Stephens DS, et al. Meningococcal disease. N Engl J Med. 2001;344(18):1378–1388.
   PubMed Web of Science ®Google Scholar
• Cohn AC, MacNeil JR, Clark TA, et al. Prevention and control of meningococcal disease: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 2013;62(RR–2):1–28.
   PubMed Web of Science ®Google Scholar
• Bexsero (MenB-4C). GlaxoSmithKline Vaccines srl. Siena, Italy: 2018.
   Google Scholar
• Chen WH, Neuzil KM, Boyce CR, et al. Safety and immunogenicity of a pentavalent meningococcal conjugate vaccine containing serogroups A, C, Y, W, and X in healthy adults: a phase 1, single-centre, double-blind, randomised, controlled study. Lancet Infect Dis. 2018;18(10):1088–1096.
   PubMed Web of Science ®Google Scholar
• Findlow J, Lucidarme J, Taha M-K, et al. Correlates of protection for meningococcal surface protein vaccines: lessons from the past. Expert Rev Vaccines. 2021;1–13. doi:https://doi.org/10.1080/14760584.2021.1940144.
   Web of Science ®Google Scholar
• Stephens DS. Biology and pathogenesis of the evolutionarily successful, obligate human bacterium Neisseria meningitidis. Vaccine. 2009;27(suppl 2):B71–7.
   PubMed Web of Science ®Google Scholar
• Borrow R, Carlone GM, Rosenstein N, et al. Neisseria meningitidis group B correlates of protection and assay standardization–international meeting report Emory University, Atlanta, Georgia, United States, 16-17 March 2005. Vaccine. 2006;24(24):5093–5107.
   PubMed Web of Science ®Google Scholar
• Finne J, Leinonen M, Makela PH. Antigenic similarities between brain components and bacteria causing meningitis. Implications for vaccine development and pathogenesis. Lancet. 1983;2(8346):355–357.
   PubMed Web of Science ®Google Scholar
• Findlow J, Bayliss CD, Beernink PT, et al. Broad vaccine protection against Neisseria meningitidis using factor H binding protein. Vaccine. 2020;38(49):7716–7727.
   PubMed Web of Science ®Google Scholar
• Sierra GV, Campa HC, Varcacel NM, et al. Vaccine against group B Neisseria meningitidis: protection trial and mass vaccination results in Cuba. NIPH Ann. 1991;14(2):195–207. Discussion 208-10.
   PubMedGoogle Scholar
• Bjune G, Høiby EA, Grønnesby JK, et al. Effect of outer membrane vesicle vaccine against group B meningococcal disease in Norway. Lancet. 1991;338(8775):1093–1096.
   PubMed Web of Science ®Google Scholar
• Holst J, Oster P, Arnold R, et al. Vaccines against meningococcal serogroup B disease containing outer membrane vesicles (OMV): lessons from past programs and implications for the future. Hum Vaccin Immunother. 2013;9(6):1241–1253.
   PubMed Web of Science ®Google Scholar
• Wang NY, Pollard AJ. The next chapter for group B meningococcal vaccines. Crit Rev Microbiol. 2018;44(1):95–111.
   PubMed Web of Science ®Google Scholar
• Holst J, Feiring B, Fuglesang JE, et al. Serum bactericidal activity correlates with the vaccine efficacy of outer membrane vesicle vaccines against Neisseria meningitidis serogroup B disease. Vaccine. 2003;21(7–8):734–737.
   PubMedGoogle Scholar
• Donald RG, Hawkins JC, Hao L, et al. Meningococcal serogroup B vaccines: estimating breadth of coverage. Hum Vaccin Immunother. 2017;13(2):255–265.
   PubMed Web of Science ®Google Scholar
• Boutriau D, Poolman J, Borrow R, et al. Immunogenicity and safety of three doses of a bivalent (B:4:p1.19,15 and B:4:p1.7-2,4) meningococcal outer membrane vesicle vaccine in healthy adolescents. Clin Vaccin Immunol. 2007;14(1):65–73.
   PubMed Web of Science ®Google Scholar
• de Kleijn ED, de Groot R, Labadie J, et al. Immunogenicity and safety of a hexavalent meningococcal outer-membrane-vesicle vaccine in children of 2-3 and 7-8 years of age. Vaccine. 2000;18(15):1456–1466.
   PubMed Web of Science ®Google Scholar
• Kaaijk P, van Straaten I, van de Waterbeemd B, et al. Preclinical safety and immunogenicity evaluation of a nonavalent PorA native outer membrane vesicle vaccine against serogroup B meningococcal disease. Vaccine. 2013;31(7):1065–1071.
   PubMed Web of Science ®Google Scholar
• Rots NY, Kleijne DE. Safety of a nonavalent meningococcal serogroup B vaccine in healthy adult volunteers in a randomised, controlled, single blind study. In 16th International Pathogenic Neisseria Conference. 2008. Rotterdam, Netherlands.
   Google Scholar
• US Food and Drug Administration. Summary Basis for Regulatory Action. 2014 October 29. [cited 2018 Oct 11]; Available from: https://wayback.archive-it.org/7993/20190425012126/https://www.fda.gov/downloads/BiologicsBloodVaccines/Vaccines/ApprovedProducts/UCM424125.pdf.
   Google Scholar
• Snape MD, Dawson T, Oster P, et al. Immunogenicity of two investigational serogroup B meningococcal vaccines in the first year of life: a randomized comparative trial. Pediatr Infect Dis J. 2010;29(11):71–79.
   PubMed Web of Science ®Google Scholar
• Findlow J, Borrow R, Snape MD, et al. Multicenter, open-label, randomized phase II controlled trial of an investigational recombinant meningococcal serogroup B vaccine with and without outer membrane vesicles, administered in infancy. Clin Infect Dis. 2010;51(10):1127–1137.
   PubMed Web of Science ®Google Scholar
• De Wals P, Deceuninck G, Lefebvre B, et al. Impact of an immunization campaign to control an increased incidence of serogroup B meningococcal disease in one region of Quebec, Canada. Clin Infect Dis. 2017;64(9):1263–1267.
   PubMed Web of Science ®Google Scholar
• Azzari C, Moriondo M, Nieddu F, et al. Effectiveness and impact of the 4CMenB vaccine against group B meningococcal disease in two Italian regions using different vaccination schedules: a five-year retrospective observational study (2014-2018). Vaccines (Basel). 2020;8(3):469.
   Web of Science ®Google Scholar
• Ladhani SN, Andrews N, Parikh SR, et al. Vaccination of infants with meningococcal group B vaccine (4CMenB) in England. N Engl J Med. 2020;382(4):309–317.
   PubMed Web of Science ®Google Scholar
• Bexsero®. Summary of Product Characteristics. GlaxoSmithKline, in 4CMenB. 2019.
   Google Scholar
• Giuliani MM, Adu-Bobie J, Comanducci M, et al. A universal vaccine for serogroup B meningococcus. Proc Natl Acad Sci U S A. 2006;103(29):10834–10839.
   PubMed Web of Science ®Google Scholar
• European Medicines Agency. Bexsero EPAR summary for the public. 2012. [cited 2017 Mar 27]; Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Summary_for_the_public/human/002333/WC500137857.pdf.
   Google Scholar
• Fletcher LD, Bernfield L, Barniak V, et al. Vaccine potential of the Neisseria meningitidis 2086 lipoprotein. Infect Immun. 2004;72(4):2088–2100.
   PubMed Web of Science ®Google Scholar
• Luo Y, Friese OV, Runnels HA, et al, The dual role of lipids of the lipoproteins in Trumenba, a self-adjuvanting vaccine against meningococcal meningitis B disease. AAPS J. 2016;18(6):1562–1575.
   PubMed Web of Science ®Google Scholar
• Zlotnick GW, Jones TR, Liberator P, et al. The discovery and development of a novel vaccine to protect against Neisseria meningitidis serogroup B disease. Hum Vaccin Immunother. 2015;11(1):5–13.
   PubMed Web of Science ®Google Scholar
• Murphy E, Andrew L, Lee K-L, et al. Sequence diversity of the factor H binding protein vaccine candidate in epidemiologically relevant strains of serogroup B Neisseria meningitidis. J Infect Dis. 2009;200(3):379–389.
   PubMed Web of Science ®Google Scholar
• Jiang HQ, Hoiseth SK, Harris SL, et al. Broad vaccine coverage predicted for a bivalent recombinant factor H binding protein based vaccine to prevent serogroup B meningococcal disease. Vaccine. 2010;28(37):6086–6093.
   PubMed Web of Science ®Google Scholar
• Vogel U, Taha M-K, Vazquez JA, et al. Predicted strain coverage of a meningococcal multicomponent vaccine (4CMenB) in Europe: a qualitative and quantitative assessment. Lancet Infect Dis. 2013;13(5):416–425.
   PubMed Web of Science ®Google Scholar
• McNeil LK, Donald RGK, Gribenko A, et al. Predicting the susceptibility of meningococcal serogroup B isolates to bactericidal antibodies elicited by bivalent rLP2086, a novel prophylactic vaccine. MBio. 2018;9(2):e00036–18.
   PubMed Web of Science ®Google Scholar
• Seib KL, Serruto D, Oriente F, et al. Factor H-binding protein is important for meningococcal survival in human whole blood and serum and in the presence of the antimicrobial peptide LL-37. Infect Immun. 2009;77(1):292–299.
   PubMed Web of Science ®Google Scholar
• Madico G, Welsch JA, Lewis LA, et al. The meningococcal vaccine candidate GNA1870 binds the complement regulatory protein factor H and enhances serum resistance. J Immunol. 2006;177(1):501–510.
   PubMed Web of Science ®Google Scholar
• Neisseria factor H binding protein sequence typing. 2020. [cited 2020 Oct 12]; Available from: https://pubmlst.org/neisseria/fHbp/.
   Google Scholar
• Jolley KA, Bray JE, Maiden MCJ. Open-access bacterial population genomics: bIGSdb software, the PubMLST.org website and their applications. Wellcome Open Res. 2018;3:124. https://wellcomeopenresearch.org/
   PubMedGoogle Scholar
• Masignani V, Comanducci M, Giuliani MM, et al. Vaccination against Neisseria meningitidis using three variants of the lipoprotein GNA1870. J Exp Med. 2003;197(6):789–799.
   PubMed Web of Science ®Google Scholar
• Brunelli B, Del Tordello E, Palumbo E, et al. Influence of sequence variability on bactericidal activity sera induced by factor H binding protein variant 1.1. Vaccine. 2011;29(5):1072–1081.
   PubMed Web of Science ®Google Scholar
• Biolchi A, Tomei S, Santini L, et al. Four-component meningococcal serogroup B vaccine induces antibodies with bactericidal activity against diverse outbreak strains in adolescents. Pediatr Infect Dis J. 2021;40(2):e66–e71.
   PubMed Web of Science ®Google Scholar
• Giuntini S, Lujan E, Gibani MM, et al. Serum bactericidal antibody responses of adults immunized with the MenB-4C vaccine against genetically diverse serogroup B meningococci. Clin Vaccin Immunol. 2017;24(1):e00430–16.
   PubMedGoogle Scholar
• NadA sequence typing. 2020. [cited 2020 Oct 12]; Available from: https://pubmlst.org/neisseria/NadA/.
   Google Scholar
• Neisserial heparin binding antigen (NHBA) protein sequence typing. 2020. [cited 2020 Oct 12]; Available from: https://pubmlst.org/neisseria/NHBA/.
   Google Scholar
• Bambini S, De Chiara M, Muzzi A, et al. Neisseria adhesin A variation and revised nomenclature scheme. Clin Vaccine Immunol. 2014;21(7):966–971.
   PubMedGoogle Scholar
• Liguori A, Dello Iacono L, Maruggi G, et al. NadA3 structures reveal undecad coiled coils and LOX1 binding regions competed by meningococcus B vaccine-elicited human antibodies. mBio. 2018;9(5):e01914–18.
   PubMedGoogle Scholar
• Partridge E, Lujan E, Giuntini S, et al. The role of anti-NHba antibody in bactericidal activity elicited by the meningococcal serogroup B vaccine, MenB-4C. Vaccine. 2017;35(33):4236–4244.
   PubMed Web of Science ®Google Scholar
• Donnelly J, Medini D, Boccadifuoco G, et al. Qualitative and quantitative assessment of meningococcal antigens to evaluate the potential strain coverage of protein-based vaccines. Proc Natl Acad Sci U S A. 2010;107(45):19490–19495.
   PubMed Web of Science ®Google Scholar
• Fagnocchi L, Biolchi A, Ferlicca F, et al. Transcriptional regulation of the nadA gene in Neisseria meningitidis impacts the prediction of coverage of a multicomponent meningococcal serogroup B vaccine. Infect Immun. 2013;81(2):560–569.
   PubMed Web of Science ®Google Scholar
• Sacchi CT, Whitney AM, Popovic T, et al. Diversity and prevalence of PorA types in Neisseria meningitidis serogroup B in the United States, 1992–1998. J Infect Dis. 2000;182(4):1169–1176.
   PubMed Web of Science ®Google Scholar
• Martin DR, Ruijne N, McCallum L, et al. The VR2 epitope on the PorA P1.7-2,4 protein is the major target for the immune response elicited by the strain-specific group B meningococcal vaccine MeNZB. Clin Vaccine Immunol. 2006;13(4):486–491.
   PubMedGoogle Scholar
• Ruijne N, Lea RA, O’Hallahan J, et al. Understanding the immune responses to the meningococcal strain-specific vaccine MeNZB measured in studies of infants. Clin Vaccine Immunol. 2006;13(7):797–801.
   PubMedGoogle Scholar
• Rajam G, Stella M, Kim E, et al. Meningococcal Antigen Typing System (MATS)-based Neisseria meningitidis serogroup B coverage prediction for the MenB-4C vaccine in the United States. mSphere. 2017;2(6):e00261-17.
   PubMed Web of Science ®Google Scholar
• Toneatto D, Ismaili S, Ypma E, et al. The first use of an investigational multicomponent meningococcal serogroup B vaccine (4CMenB) in humans. Hum Vaccin. 2011;7(6):646–653.
   PubMed Web of Science ®Google Scholar
• Wedege E, Bolstad K, Aase A, et al. Functional and specific antibody responses in adult volunteers in New Zealand who were given one of two different meningococcal serogroup B outer membrane vesicle vaccines. Clin Vaccin Immunol. 2007;14(7):830–838.
   PubMedGoogle Scholar
• Giuliani M, Bartolini E, Galli B, et al. Human protective response induced by meningococcus B vaccine is mediated by the synergy of multiple bactericidal epitopes. Sci Rep. 2018;8(1):3700.
   PubMed Web of Science ®Google Scholar
• Harris SL, Tan C, Andrew L, et al. The bivalent factor H binding protein meningococcal serogroup B vaccine elicits bactericidal antibodies against representative non-serogroup B meningococci. Vaccine. 2018;36(45):6867–6874.
   PubMed Web of Science ®Google Scholar
• Ladhani SN, Campbell H, Andrews N, et al. First real-world evidence of meningococcal group B vaccine, 4CMenB, protection against meningococcal group W disease; prospective enhanced national surveillance, England. Clin Infect Dis. 2021;73(7):e1661–e1668.
   PubMed Web of Science ®Google Scholar
• Taha M-K, Hawkins JC, Liberator P, et al. Bactericidal activity of sera from adolescents vaccinated with bivalent rLP2086 against meningococcal serogroup B outbreak strains from France. Vaccine. 2017;35(11):1530–1537.
   PubMed Web of Science ®Google Scholar
• Lujan E, Partridge E, Giuntini S, et al. Breadth and duration of meningococcal serum bactericidal activity in health care workers and microbiologists immunized with the MenB-FHbp vaccine. Clin Vaccine Immunol. 2017;24(8):e00121–17.
   PubMedGoogle Scholar
• Ostergaard L, Vesikari T, Absalon J, et al. A bivalent meningococcal B vaccine in adolescents and young adults. N Engl J Med. 2017;347(24):2349–2362.
   Google Scholar
• Santolaya ME, O'Ryan ML, Valenzuela MT, et al. Imunogenicity and tolerability of a multicomponent meningococcal serogroup B (4CMenB) vaccine in healthy adolescents in Chile: a phase 2b/3 randomised, observer-blind, placebo-controlled study. Lancet. 2012;379(9816):617–24.
   PubMed Web of Science ®Google Scholar
• Pizza M, Scarlato V, Masignani V, et al. Identification of vaccine candidates against serogroup B meningococcus by whole-genome sequencing. Science. 2000;287(5459):1816–1820.
   PubMed Web of Science ®Google Scholar
• O’Ryan M, Stoddard J, Toneatto D, et al. A multi-component meningococcal serogroup B vaccine (4CMenB): the clinical development program. Drugs. 2014;74(1):15–30.
   PubMed Web of Science ®Google Scholar
• Masignani V, Pizza M, Moxon ER. The development of a vaccine against meningococcus B using reverse vaccinology. Front Immunol. 2019;10:751.
   PubMed Web of Science ®Google Scholar
• Giuliani MM, Biolchi A, Serruto D, et al. Measuring antigen-specific bactericidal responses to a multicomponent vaccine against serogroup B meningococcus. Vaccine. 2010;28(31):5023–5030.
   PubMed Web of Science ®Google Scholar
• Medini D, Stella M, Wassil J. MATS: global coverage estimates for 4CMenB, a novel multicomponent meningococcal B vaccine. Vaccine. 2015;33(23):2629–2636.
   PubMed Web of Science ®Google Scholar
• da Silva RAG, Karlyshev, AV, Oldfield, NL. Variant signal peptides of vaccine antigen, FHbp, impair processing affecting surface localization and antibody-mediated killing in most meningococcal isolates. Front Microbiol. 2019;10:2847.
   PubMedGoogle Scholar
• Basta N, Mahmoud AAF, Wolfson J, et al. Immunogenicity of a meningococcal B vaccine during a university outbreak. N Engl J Med. 2016;375(3):220–228.
   PubMed Web of Science ®Google Scholar
• Borrow R, Taha M-K, Giuliani MM, et al. Methods to evaluate serogroup B meningococcal vaccines: from predictions to real-world evidence J Infect. 2020;81(6):862–872.
   PubMed Web of Science ®Google Scholar
• Muzzi A, Brozzi A, Serino L, et al. Genetic Meningococcal Antigen Typing System (gMATS): a genotyping tool that predicts 4CMenB strain coverage worldwide. Vaccine. 2019;37(7):991–1000.
   PubMed Web of Science ®Google Scholar
• Brehony C, Rodrigues CMC, Borrow R, et al. Distribution of Bexsero® Antigen Sequence Types (BASTs) in invasive meningococcal disease isolates: implications for immunisation. Vaccine. 2016;34(39):4690–4697.
   PubMed Web of Science ®Google Scholar
• Rodrigues CMC, Jolley, KA, Smith, A, et al. Meningococcal Deduced Vaccine Antigen Reactivity (MenDeVAR) index: a rapid and accessible tool that exploits genomic data in public health and clinical microbiology applications. J Clin Microbiol. 2020;59(1):e02161–20.
   PubMedGoogle Scholar
• Martinón-Torres F, Carmona Martinez A, Simkó R, et al. Antibody persistence and booster responses 24-36 months after different 4CMenB vaccination schedules in infants and children: a randomised trial. J Infect. 2018;76(3):258–269.
   PubMed Web of Science ®Google Scholar
• Martinón-Torres F, Nolan T, Toneatto D, et al. Persistence of the immune response after 4CMenB vaccination, and the response to an additional booster dose in infants, children, adolescents, and young adults. Hum Vaccin Immunother. 2019;15(12):2940–2951.
   PubMed Web of Science ®Google Scholar
• Nolan T, Santolaya ME, de Looze F, et al. Antibody persistence and booster response in adolescents and young adults 4 and 7.5 years after immunization with 4CMenB vaccine. Vaccine. 2019;37(9):1209–1218.
   PubMed Web of Science ®Google Scholar
• Findlow J, Bai X, Findlow H, et al. Safety and immunogenicity of a four-component meningococcal group B vaccine (4CMenB) and a quadrivalent meningococcal group ACWY conjugate vaccine administered concomitantly in healthy laboratory workers. Vaccine. 2015;33(29):3322–3330.
   PubMed Web of Science ®Google Scholar
• Read RC, Dull P, Bai X, et al. A phase III observer-blind randomized, controlled study to evaluate the immune response and the correlation with nasopharyngeal carriage after immunization of university students with a quadrivalent meningococcal ACWY glycoconjugate or serogroup B meningococcal vaccine. Vaccine. 2017;35(3):427–434.
   PubMed Web of Science ®Google Scholar
• Szenborn L, Block SL, Jackowska T, et al. Immune responses to booster vaccination with meningococcal ABCWY vaccine after primary vaccination with either investigational or licensed vaccines: a phase 2 randomized study. Pediatr Infect Dis J. 2018;37(5):475–482.
   PubMed Web of Science ®Google Scholar
• Toneatto D, Oster P, deBoer ACW, et al. Early clinical experience with a candidate meningococcal B recombinant vaccine (rMenB) in healthy adults. Hum Vaccin. 2011;7(7):781–791.
   PubMed Web of Science ®Google Scholar
• Perez JL, Absalon J, Beeslaar J, et al. From research to licensure and beyond: clinical development of MenB-FHbp, a broadly protective meningococcal B vaccine. Expert Rev Vaccines. 2018;17(6):461–477.
   PubMed Web of Science ®Google Scholar
• Harris SL, Tan C, Perez J, et al. Selection of diverse strains to assess broad coverage of the bivalent FHbp meningococcal B vaccine. NPJ Vaccines. 2020;5(1):8.
   PubMed Web of Science ®Google Scholar
• Richmond PC, Marshall HS, Nissen MD, et al. Safety, immunogenicity, and tolerability of meningococcal serogroup B bivalent recombinant lipoprotein 2086 vaccine in healthy adolescents: a randomised, single-blind, placebo-controlled, phase 2 trial. Lancet Infect Dis. 2012;12(8):597–607.
   PubMed Web of Science ®Google Scholar
• Abad R, García-Amil C, Navarro C, et al. Molecular characterization of invasive serogroup B Neisseria meningitidis isolates from Spain during 2015-2018: evolution of the vaccine antigen factor H binding protein (FHbp). J Infect. 2021;82(4):37–44.
   PubMed Web of Science ®Google Scholar
• Bettinger JA, Liberator P, Halperin SA, et al. Estimated susceptibility of Canadian meningococcal B isolates to a meningococcal serogroup B vaccine (MenB-FHbp). Vaccine. 2020;38(8):2026–2033.
   PubMed Web of Science ®Google Scholar
• Carannante A, Fazio C, Neri A, et al. Meningococcal B vaccine antigen FHbp variants among disease-causing Neisseria meningitidis B isolates, Italy, 2014-2017. PLoS One. 2020;15(11):e0241793.
   PubMed Web of Science ®Google Scholar
• de Lemos APS, Sacchi CT, Gonçalves CR, et al. Genomic surveillance of Neisseria meningitidis serogroup B invasive strains: diversity of vaccine antigen types, Brazil, 2016-2018. PLoS One. 2020;15(12):e0243375.
   PubMed Web of Science ®Google Scholar
• Tzanakaki G, Xirogianni A, Tsitsika A, et al. Estimated strain coverage of serogroup B meningococcal vaccines: a retrospective study for disease and carrier strains in Greece (2010-2017). Vaccine. 2021;39(11):1621–1630.
   PubMed Web of Science ®Google Scholar
• Harris SL, Donald RGK, Hawkins JC, et al. Neisseria meningitidis serogroup B vaccine, bivalent rLP2086, induces broad serum bactericidal activity against diverse invasive disease strains including outbreak strains. Pediatr Infect Dis J. 2017;36(2):216–223.
   PubMed Web of Science ®Google Scholar
• McNamara LA, Shumate AM, Johnsen P, et al. First use of a serogroup B meningococcal vaccine in the US in response to a university outbreak. Pediatrics. 2015;135(5):798–804.
   PubMed Web of Science ®Google Scholar
• Basta N, Mahmoud, A, Wolfson, J, et al. Meningococcal B vaccine (4CMenB) immunogenicity pre- and postvaccination among university students in the US. Presented at: 36th Annual European Society for Paediatric Infectious Diseases (ESPID) Meeting; May 28-June 2, 2018; Malmo Sweden.
   Google Scholar
• Biolchi A, Tomei S, Santini L, et al. Evaluation of strain coverage of the multicomponent meningococcal serogroup B vaccine (4CMenB) administered in infants according to different immunisation schedules. Hum Vaccin Immunother. 2019;15(3):725–731.
   PubMed Web of Science ®Google Scholar
• Pfizer Inc. Data on file: Final Clinical Study Report: a phase 4, single-arm, open-label study describing the safety and immunogenicity of Bexsero in healthy subjects aged between 12 and <19 years. B1971048. 2016.
   Google Scholar
• EU Clinical Trials Register. A Phase 4, Single-Arm, Open-Label Study Describing The Safety And Immunogenicity of Bexsero in Healthy Subjects Aged 12 Years to Less Than (<) 19 Years. [cited 2021 Mar 26]: Available from: https://www.clinicaltrialsregister.eu/ctr-search/trial/2014-003822-42/results.
   Google Scholar
• Biolchi A, De Angelis G, Moschioni M, et al. Multicomponent meningococcal serogroup B vaccination elicits cross-reactive immunity in infants against genetically diverse serogroup C, W and Y invasive disease isolates. Vaccine. 2020;38(47):7542–7550.
   PubMed Web of Science ®Google Scholar
• Biolchi A, Tomei S, Brunelli B, et al. 4CMenB immunization induces serum bactericidal antibodies against non-serogroup B meningococcal strains in adolescents. Infect Dis Ther. 2021;10(1):307–316.
   PubMed Web of Science ®Google Scholar
• Ladhani SN, Giuliani MM, Biolchi A, et al. Effectiveness of meningococcal B vaccine against endemic hypervirulent Neisseria meningitidis W strain, England. Emerg Infect Dis. 2016;22(2):309–311.
   PubMed Web of Science ®Google Scholar
• Biolchi A, Tomei S, Santini L, et al. Four-component meningococcal serogroup B vaccine induces antibodies with bactericidal activity against diverse outbreak strains in adolescents. Pediatr Infect Dis J. 2021;40(2):e66–e71.
   PubMed Web of Science ®Google Scholar
• Vaccines and Related Biologic Products Advisory Committee. Approaches to licensure of meningococcal vaccines for prevention of serogroup B invasive meningococcal disease: briefing document for the Vaccines and Related Biologic Product Advisory Committee Meeting, April 7. Silver Spring MD: US Food and Drug Administration; 2011.
   Google Scholar
• Soeters HM, McNamara LA, Blain AE, et al. University-based outbreaks of meningococcal disease caused by serogroup B, United States, 2013-2018. Emerg Infect Dis. 2019;25(3):434–440.
   PubMed Web of Science ®Google Scholar
• Borrow R, Balmer P, Miller E. Meningococcal surrogates of protection–serum bactericidal antibody activity. Vaccine. 2005;23(17–18):2222–2227.
   PubMed Web of Science ®Google Scholar
• Maiden MCJ, Ibarz-Pavón AB, Urwin R, et al. Impact of meningococcal serogroup C conjugate vaccines on carriage and herd immunity. J Infect Dis. 2008;197(5):737–743.
   PubMed Web of Science ®Google Scholar
• Marsh JW, Shutt KA, Pajon R, et al. Diversity of factor H-binding protein in Neisseria meningitidis carriage isolates. Vaccine. 2011;29(35):6049–6058.
   PubMed Web of Science ®Google Scholar
• Lemée L, Hong E, Etienne M, et al. Genetic diversity and levels of expression of factor H binding protein among carriage isolates of Neisseria meningitidis. PLoS One. 2014;9(9):e107240.
   PubMed Web of Science ®Google Scholar
• Ala’aldeen DAA, Flint M, Oldfield NJ, et al. Human antibody responses to the meningococcal factor H binding protein (LP2086) during invasive disease, colonization and carriage. Vaccine. 2010;28(48):7667–7675.
   PubMed Web of Science ®Google Scholar
• Sadarangani M, Sell T, Iro MA, et al. Persistence of immunity after vaccination with a capsular group B meningococcal vaccine in 3 different toddler schedules. CMAJ. 2017;189(41):E1276–E1285.
   PubMed Web of Science ®Google Scholar
• Iro MA, Snape MD, Voysey M, et al. Persistence of bactericidal antibodies following booster vaccination with 4CMenB at 12, 18 or 24 months and immunogenicity of a fifth dose administered at 4 years of age-a phase 3 extension to a randomised controlled trial. Vaccine. 2017;35(2):395–402.
   PubMed Web of Science ®Google Scholar
• Snape MD, Voysey M, Finn A, et al. Persistence of bactericidal antibodies after infant serogroup B meningococcal immunization and booster dose response at 12, 18 or 24 months of age. Pediatr Infect Dis J. 2016;35(4):113–123.
   PubMed Web of Science ®Google Scholar
• Vesikari T, Østergaard L, Beeslaar J, et al. Persistence and 4-year boosting of the bactericidal response elicited by two- and three-dose schedules of MenB-FHbp: a phase 3 extension study in adolescents. Vaccine. 2019;37(12):1710–1719.
   PubMed Web of Science ®Google Scholar
• Presa J, Findlow J, Vojicic J, et al. Epidemiologic trends, global shifts in meningococcal vaccination guidelines, and data supporting the use of MenACWY-TT vaccine: a review. Infect Dis Ther. 2019;8(3):307–333.
   PubMed Web of Science ®Google Scholar
• Marshall HS, McMillan M, Koehler AP, et al. Meningococcal B vaccine and meningococcal carriage in adolescents in Australia. N Engl J Med. 2020;382(4):318–327.
   PubMed Web of Science ®Google Scholar
• McMillan M, Walters L, Sullivan T, et al. Impact of meningococcal B (4CMenB) vaccine on pharyngeal Neisseria meningitidis carriage density and persistence in adolescents. Clin Infect Dis. 2021; 73(1):e99–e106.
   PubMed Web of Science ®Google Scholar
• Soeters HM, Whaley M, Alexander-Scott N, et al. Meningococcal carriage evaluation in response to a serogroup B meningococcal disease outbreak and mass vaccination campaign at a college-Rhode Island, 2015-2016. Clin Infect Dis. 2017;64(8):1115–1122.
   PubMed Web of Science ®Google Scholar
• McNamara LA, Thomas JD, MacNeil J, et al. Meningococcal carriage following a vaccination campaign with MenB-4C and MenB-FHbp in response to a university serogroup B meningococcal disease outbreak-Oregon, 2015-2016. J Infect Dis. 2017;216(9):1130–1140.
   PubMed Web of Science ®Google Scholar
• Carr J, Plested E, Aley P, et al. ‘Be on the TEAM’ Study (Teenagers Against Meningitis): protocol for a controlled clinical trial evaluating the impact of 4CMenB or MenB-fHbp vaccination on the pharyngeal carriage of meningococci in adolescents. BMJ Open. 2020;10(10):e037358.
   PubMed Web of Science ®Google Scholar
• Goldschneider I, Gotschlich EC, Artenstein MS. Human immunity to the meningococcus. I. the role of humoral antibodies. J Exp Med. 1969;129(6):1307–1326.
   PubMed Web of Science ®Google Scholar
• TRUMENBA® (Meningococcal Group B Vaccine). Full Prescribing Information, Wyeth Pharmaceuticals LLC, a subsidiary of Pfizer Inc. Philadelphia PA; 2018.
   Google Scholar
• Sáez-Llorens X, Beltran-Rodriguez J, Novoa Pizarro JM, et al. Four-year antibody persistence and response to a booster dose of a pentavalent MenABCWY vaccine administered to healthy adolescents and young adults. Hum Vaccin Immunother. 2018;14(5):1161–1174.
   PubMed Web of Science ®Google Scholar
• Peterson J, Drazan D, Czajka H, et al. Pentavalent meningococcal (MenABCWY) vaccine is safe and well tolerated with immunogenicity noninferior to coadministered MenB-FHbp and MenACWY-CRM in a phase 2 study of healthy adolescents and young adults. Open Forum Infect Dis. 2020;7(Suppl 1):S25–S26.
   Google Scholar
• Tzeng Y-L, Giuntini S, Berman Z, et al. Neisseria meningitidis urethritis outbreak isolates express a novel factor H binding protein variant that is a potential target of group B-directed meningococcal (MenB) vaccines. Infect Immun. 2020;88(12):e00462–20.
   PubMedGoogle Scholar